The FDA has approved upadacitinib for the treatment of non-radiographic axial spondylarthritis, marking the sixth indication for the therapy, according to a press release from AbbVie.
“This latest FDA approval of Rinvoq in active [non-radiographic axial SpA (nr-axSpA)] provides a new oral, once daily treatment option for patients who historically have had limited treatment options for this painful, chronic disease,” Thomas Hudson, MD, senior vice president of research and development, and chief scientific officer, for AbbVie, said in the release. “Rinvoq is now approved to